BRIEF—Immunology start-up names CEO

Tridek-One, an immunology start-up that was set up last year has named Philippe Berthon as chief executive.

Dr Berthon has more than 25 years of experience in biotechnology in various management positions, including R&D and corporate finance, and has been chief executive of three other companies. He was also co-founder and director of the Onco-Urology Research Laboratory at the Saint-Louis Hospital in Paris.

Tridek-One is a French company developing a CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions, and recently announced a three million euros ($3.4 million) funding round.

"Joining such a talented scientific team already supported by leading European venture funds as Advent France Biotechnology and Advent Life Sciences is a really challenging opportunity," Dr Berthon said.